C4 Therapeutics, Inc. financial data

Symbol
CCCC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
490 Arsenal Way, Suite 120, Watertown, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 595 % -13.8%
Debt-to-equity 55.4 % +18.8%
Return On Equity -52.9 % -22.2%
Return On Assets -34 % -15.3%
Operating Margin -674 % -36.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.8M shares +40.2%
Common Stock, Shares, Outstanding 68.8M shares +40.2%
Entity Public Float 130M USD -35.6%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 68.4M shares +39.6%
Weighted Average Number of Shares Outstanding, Diluted 68.4M shares +39.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 20M USD -26.3%
Research and Development Expense 111M USD -7.86%
General and Administrative Expense 41.4M USD +1.25%
Operating Income (Loss) -135M USD -0.47%
Nonoperating Income (Expense) 10.2M USD +234%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -28.4M USD +18.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -126M USD +4.01%
Earnings Per Share, Basic -2.37 USD/shares +11.6%
Earnings Per Share, Diluted -2.37 USD/shares +11.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 89.7M USD +81.2%
Marketable Securities, Current 264M USD +10.4%
Cash, Cash Equivalents, and Short-term Investments 299M USD -1.9%
Accounts Receivable, after Allowance for Credit Loss, Current 13.6M USD +2476%
Assets, Current 280M USD +0.41%
Property, Plant and Equipment, Net 6.76M USD -11.6%
Operating Lease, Right-of-Use Asset 62.4M USD -9.07%
Other Assets, Noncurrent 5.23M USD +55.6%
Assets 398M USD +0.59%
Accounts Payable, Current 1.63M USD +57.6%
Contract with Customer, Liability, Current 35.1M USD +135%
Liabilities, Current 55M USD +39.7%
Contract with Customer, Liability, Noncurrent 20.7M USD +30.7%
Operating Lease, Liability, Noncurrent 64.4M USD -7.68%
Liabilities 140M USD +4.88%
Accumulated Other Comprehensive Income (Loss), Net of Tax -380K USD +84.6%
Retained Earnings (Accumulated Deficit) -557M USD -29.3%
Stockholders' Equity Attributable to Parent 258M USD -1.6%
Liabilities and Equity 398M USD +0.59%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.1M USD +45.3%
Net Cash Provided by (Used in) Financing Activities 34.6M USD
Net Cash Provided by (Used in) Investing Activities -53.4M USD -200%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 68.8M shares +40.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -36.9M USD -287%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 93.1M USD +76.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 146M USD +32.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 166M USD +25.9%
Operating Lease, Liability 71M USD -6.2%
Depreciation 1.48M USD -22.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -124M USD +4.74%
Lessee, Operating Lease, Liability, to be Paid 89M USD -8.78%
Property, Plant and Equipment, Gross 14.9M USD -8.18%
Operating Lease, Liability, Current 5.36M USD +10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.09M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.83M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.1M USD -17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.37M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 61M USD +12.4%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 1.28M USD
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.65M USD +2.99%
Operating Lease, Payments 2.18M USD +3.02%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 76K USD
Current Federal Tax Expense (Benefit) 0 USD
Share-based Payment Arrangement, Expense 27.2M USD -0.48%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%